Skin and soft tissue infections (SSTIs) are common and may be more severe in patients with diabetes. In particular, the development of diabetic foot ulcers facilitates diabetic foot infections (DFIs), which are generally not included in SSTI classifications (1). In these situations, gram-negative bacilli (GNB) may have an impact on the etiology of severe SSTIs.

We aimed to analyze the GNB etiology, epidemiologic trends, and risk factors for mortality among a large cohort of adult patients with diabetes attended in our hospital (1996–2016) with bloodstream infections from an SSTI source (1). Cases with nosocomial acquisition or due to a sacral decubitus ulcer were excluded.

Out of 30,363 episodes of bacteremia, 7,202 (23.7%) occurred in patients with diabetes; this proportion increased over time from 17.7% in 1996–2000 to 28.3% in 2011–2016 (P < 0.001). Among bacteremic episodes in patients with diabetes, 247 (3.4%) were secondary to SSTIs, of which 223 were analyzed (Table 1). The most common clinical form was cellulitis (n = 184, 82.5%). DFIs represented 25% of cases (with abscesses in 23%), of which 41.8% required surgery (amputation, 43.5%).

Table 1

Clinical characteristics of the studied cohort and differences between patients with an infection due to GNB, GPC, or mixed polymicrobial infection

Total (N = 223)Mixed polymicrobial infections (n = 17; 7.6%)GNB (n = 68; 30.5%)GPC (n = 138; 61.9%)P valuea
Demographic characteristics      
 Age, mean (years) 67.1 70.1 72.1 64.7 <0.001 
 Women 92 (41.3) 7 (41.2) 29 (42.7) 56 (40.6) 0.777 
Characteristics of diabetes and secondary complicationsb      
 Insulin dependent 126 (58.9) 10 (58.8) 43 (65.2) 73 (55.7) 0.204 
 Diabetic complications 129 (57.9) 14 (82.4) 46 (67.7) 69 (50) 0.016 
 Coronary disease 44 (19.9) 4 (23.5) 13 (19.1) 27 (19.9) 0.901 
 Cerebrovascular disease 20 (9.1) 6 (35.3) 9 (13.2) 5 (3.7) 0.011 
 Diabetic nephropathyc 51 (23.1) 3 (17.7) 25 (36.8) 23 (16.9) 0.002 
 Peripheral arterial disease 75 (33.9) 10 (58.8) 25 (36.8) 40 (29.4) 0.288 
Type of infection      
 Cellulitis 184 (82.5) 11 (64.7) 58 (85.3) 115 (83.3) 0.718 
 Abscesses 33 (14.8) 2 (11.8) 8 (11.8) 23 (16.7) 0.355 
 Necrotizing fasciitis 23 (10.3) 4 (23.5) 8 (11.8) 11 (8) 0.376 
 Pyomyositis 10 (4.5) 0 (0) 4 (5.9) 6 (4.4) 0.630 
 DFIs 56 (25.1) 11 (64.7) 13 (19.1) 32 (23.2) 0.506 
Characteristics of the infection      
 Presence of ulcer as portal of entry 104 (47.1) 15 (88.2) 32 (47.1) 57 (41.9) 0.485 
 Location of infection on the lower extremity 183 (82.1) 16 (94.1) 63 (92.7) 104 (75.4) 0.003 
 Presence of SIRS on admissiond 52 (23.3) 9 (52.9) 23 (33.8) 20 (14.5) 0.001 
 Received antibiotics previously 81 (36.3) 6 (35.3) 38 (55.9) 37 (26.8) <0.001 
 Health care–related infectione 73 (32.7) 5 (29.4) 36 (52.9) 32 (23.2) <0.001 
 Surgical treatment 67 (30.32) 7 (41.2) 18 (26.9) 42 (30.7) 0.577 
 Overall mortality (at 30 days) 48 (21.5) 7 (41.2) 22 (32.4) 19 (13.8) 0.002 
Total (N = 223)Mixed polymicrobial infections (n = 17; 7.6%)GNB (n = 68; 30.5%)GPC (n = 138; 61.9%)P valuea
Demographic characteristics      
 Age, mean (years) 67.1 70.1 72.1 64.7 <0.001 
 Women 92 (41.3) 7 (41.2) 29 (42.7) 56 (40.6) 0.777 
Characteristics of diabetes and secondary complicationsb      
 Insulin dependent 126 (58.9) 10 (58.8) 43 (65.2) 73 (55.7) 0.204 
 Diabetic complications 129 (57.9) 14 (82.4) 46 (67.7) 69 (50) 0.016 
 Coronary disease 44 (19.9) 4 (23.5) 13 (19.1) 27 (19.9) 0.901 
 Cerebrovascular disease 20 (9.1) 6 (35.3) 9 (13.2) 5 (3.7) 0.011 
 Diabetic nephropathyc 51 (23.1) 3 (17.7) 25 (36.8) 23 (16.9) 0.002 
 Peripheral arterial disease 75 (33.9) 10 (58.8) 25 (36.8) 40 (29.4) 0.288 
Type of infection      
 Cellulitis 184 (82.5) 11 (64.7) 58 (85.3) 115 (83.3) 0.718 
 Abscesses 33 (14.8) 2 (11.8) 8 (11.8) 23 (16.7) 0.355 
 Necrotizing fasciitis 23 (10.3) 4 (23.5) 8 (11.8) 11 (8) 0.376 
 Pyomyositis 10 (4.5) 0 (0) 4 (5.9) 6 (4.4) 0.630 
 DFIs 56 (25.1) 11 (64.7) 13 (19.1) 32 (23.2) 0.506 
Characteristics of the infection      
 Presence of ulcer as portal of entry 104 (47.1) 15 (88.2) 32 (47.1) 57 (41.9) 0.485 
 Location of infection on the lower extremity 183 (82.1) 16 (94.1) 63 (92.7) 104 (75.4) 0.003 
 Presence of SIRS on admissiond 52 (23.3) 9 (52.9) 23 (33.8) 20 (14.5) 0.001 
 Received antibiotics previously 81 (36.3) 6 (35.3) 38 (55.9) 37 (26.8) <0.001 
 Health care–related infectione 73 (32.7) 5 (29.4) 36 (52.9) 32 (23.2) <0.001 
 Surgical treatment 67 (30.32) 7 (41.2) 18 (26.9) 42 (30.7) 0.577 
 Overall mortality (at 30 days) 48 (21.5) 7 (41.2) 22 (32.4) 19 (13.8) 0.002 

Data are n (%) unless otherwise indicated.

a

Comparison between GNB and GPC cases.

b

Glycated hemoglobin was available only in almost one-third of the cases (median 8.2% (interquartile range 6.9–10.2); thus, these data are not presented in the table.

c

Among patients with diabetic nephropathy, 21 (41.2%) had a glomerular filtration rate (GFR) between 30 and 59 mL/min/1.73 m2, 10 (19.6%) had severe impairment of renal function (GFR 15–29 mL/min/1.73 m2), and 20 (39.2%) were on hemodialysis.

d

SIRS (systemic inflammatory response syndrome) according to definition in ref. 6.

e

In accordance with definitions by Friedman et al. (7).

Regarding the microbiology, 138 (61.9%) cases were caused exclusively by gram-positive cocci (GPC) (mainly Streptococcus spp. [63.8%] and Staphylococcus aureus [29%]) and 68 (30.5%) by GNB (Escherichia coli [26.5%] and Pseudomonas spp. [26.5%]). Seventeen cases (7.6%) were polymicrobial mixed infections (combining GPC and GNB); those were excluded for specific comparison of patients with GNB SSTIs vs. GPC SSTIs (Table 1). The former were older, had higher rates of diabetic complications and health care–related infections, had received prior antibiotics more often, and had infections that were mostly located on the lower extremities.

Comparison of the 1996–2000 and 2011–2016 time periods revealed an upward trend in the prevalence of GNB SSTIs (14.3% vs. 40.6%; P = 0.020), in the previous use of antibiotics (14.3% vs. 44.9%; P = 0.003), and in the proportion of GNB resistant to frequently used antibiotics (amoxicillin-clavulanate and fluoroquinolones) (0% vs. 20.3%; P = 0.100).

The 30-day mortality rate was 21.5%, ranging from 57.9% in necrotizing fasciitis to 17.2%, 14.3%, and 10.5% in cellulitis, pyomyositis, and abscesses, respectively (P < 0.001). Mortality from DFIs was 16%. Patients with GNB SSTIs had higher mortality rates (32.4%) compared with patients with GPC SSTIs (13.8%) (P = 0.002) in all types of SSTIs but necrotizing fasciitis, which had an intrinsic high mortality independent of the etiology. In multivariate analysis after adjusting for age, sex, presence of coronary disease, type of SSTI (excluding necrotizing fasciitis), and site of acquisition, infection due to GNB was the only statistically significant risk factor for mortality (adjusted odds ratio 2.73 [95% CI 1.11–6.70]; P = 0.028).

Our study shows an increasing trend in GNB SSTIs among patients with diabetes, with consequent greater mortality. The results may be inherently limited by the retrospective review and conditioned not only by diabetes but also by other comorbidities of the patients or the presence of bacteremia itself.

The most common SSTI was cellulitis, but DFIs represented 25% and had higher rates of abscesses and need for amputation. This supports the previous opinion about considering DFIs in further classifications of SSTIs because of their frequency and particular characteristics (1).

Despite the dominance of GPC etiology, we observed a greater proportion of GNB (30.5%) than is classically reported (2). This fact seems not only related to the presence of ulcers but also the location of SSTIs on the lower extremities and the specific immunosuppressive conditions that patients with diabetes may present. Also, we recognized a significant increase in the proportion of GNB bacteremia over time, as has been noted worldwide in similar settings (3). Finally, we noticed an increase in the SSTIs caused by GNB resistant to the most commonly used antibiotics but without a specific increment in those GNB defined as multidrug resistant, thus leading us only to hypothesize about their lower virulence or a possible emergence of multidrug resistance in the future.

In our study, the mortality rates varied according to the type of SSTI and were high considering overall mortality from SSTIs but comparable to other studies with the same type of patients or with bloodstream infections (4). Notably, infections due to GNB were associated with twofold increased odds of mortality, after adjusting for other causes. These differences were detected in all types of SSTIs except necrotizing fasciitis. To our knowledge, scarce reference has been made previously to GNB etiology as an independent risk factor for mortality in SSTIs (5).

In conclusion, because of the increase in GNB infections, including those resistant to the most commonly used antibiotics, and their greater mortality, appropriate empirical coverage is mandatory, whether in patients with SSTIs and severe systemic manifestations or suspicion of bacteremia.

Acknowledgments. The authors thank John B. Warren (International House Barcelona) for revising the English manuscript.

Funding. E.B. was supported by a grant from the Spanish Ministerio de Educación, Cultura y Deporte (FI 16/00397).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. E.B. researched data, performed the analysis of the data, and wrote the manuscript. O.M., I.G., J.A., and R.P. contributed to discussion and reviewed and edited the manuscript. J.G.-J. contributed to the statistical analysis and discussion. J.L.-A., L.S., and F.T. researched data. E.B. and O.M. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. The preliminary results of this study were reported in part at the 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 21–24 April 2018.

1.
Lipsky
BA
,
Silverman
MH
,
Joseph
WS
.
A proposed new classification of skin and soft tissue infections modeled on the subset of diabetic foot infection
.
Open Forum Infect Dis
2016
;
4
:
ofw255
2.
Gunderson
CG
,
Martinello
RA
.
A systematic review of bacteremias in cellulitis and erysipelas
.
J Infect
2012
;
64
:
148
155
3.
Ho
J
,
Tambyah
PA
,
Paterson
DL
.
Multiresistant gram-negative infections: a global perspective
.
Curr Opin Infect Dis
2010
;
23
:
546
553
4.
Marwick
C
,
Broomhall
J
,
McCowan
C
, et al
.
Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients
.
J Antimicrob Chemother
2011
;
66
:
387
397
5.
Lipsky
BA
,
Tabak
YP
,
Johannes
RS
,
Vo
L
,
Hyde
L
,
Weigelt
JA
.
Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost
.
Diabetologia
2010
;
53
:
914
923
6.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference
.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
.
Crit Care Med
1992
;
20
:
864
874
7.
Friedman
ND
,
Kaye
KS
,
Stout
JE
, et al
.
Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections
.
Ann Intern Med
2001
;
137
:
791
797
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.